Based on research from Brigham Young University and University of Utah, Sera has added $36m to its funding vault to drive commercialisation of its blood testing system PreTRM.

Sera Prognostics, US-based prenatal diagnostics technology developer based on research from Brigham Young University and University of Utah, collected $36m in a series D round yesterday co-led by investment firm Blue Ox Healthcare Partners.
Two unnamed healthcare companies co-led the round, which additionally included life sciences research company Laboratory Corporation of America (LabCorp), Domain Associates, InterWest Partners, Catalyst Health Ventures and Chione.
Founded in 2008, Sera Prognostics has created a blood testing system, PreTRM, that offers  a personalised,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in